Be the first person to write a business review for Cadence Pharmaceuticals, Inc.

Calyx Bio-Ventures (formerly Chromos Molecular Systems) wants you to part with that chromosome. The company is developing therapeutic products to fight diseases based on its REM (rapid expansion method) technology. The company has sold its ACE System (artificial chromosome expression) technology but retains some rights to use the ACE System for gene therapy applications. The system's potential biopharmaceutical product applications include therapies for infectious diseases and cancers. The company emerged from bankruptcy protection in late 2007 and completed its restructuring when it merged its operations into its Calyx subsidiary the following year.

Cambrex Corporation was founded in 1981 and is based in East Rutherford, New Jersey. Cambrex Corporation, a life sciences company, provides products and services to develop and commercialize active pharmaceutical ingredients and advanced intermediates. Its products include active pharmaceutical ingredients and pharmaceutical intermediates for use in the production of prescription and over-the-counter drug products, and other custom chemicals derived from organic chemistry. The company sells its products through direct sales and independent agents to pharmaceutical and generic drug companies worldwide.

Cangene Corporation company makes plasma products known as hyperimmunes, which are antibody preparations and recombinant biopharmaceuticals made by introducing a gene in a host organism. Cangene's drugs are used to treat plasma-derived disorders, including the blood clotting disorder thrombocytopenic purpura and hemolytic disease of the newborn, which occurs when a fetus' blood type is incompatible with its mother's. Cangene has several approved products and is developing others, mainly in the areas of infectious disease and biodefense. Generic giant Apotex owns more than 80% of Cangene.

Caprius, Inc. company owns a majority interest in MCM Environmental Technologies, which provides systems for disposal of medical waste. Its SteriMed system can crush, grind, shred, and mix all types of medical waste, including metal sharps and needles, plastic tubing and IV bags, and glass items. Once this process is complete, MCM's Steri-Cid chemical process disinfects the waste, which can then be discarded as regular waste at as little as 10% of the original volume. MCM manufactures the SteriMed system in Israel; the company distributes parts and supplies from facilities in Israel. Officers and directors, led by Austin W. Marxe and David M. Greenhouse hold about 22% of Caprius.

CardioVascular BioTherapeutics, Inc. (Cardio) is a development-stage biopharmaceutical company focused on developing drugs to stimulate the growth of new blood vessels for the treatment of cardiovascular diseases. The active pharmaceutical ingredient (API) in the Company’s drug candidates is acidic human fibroblast growth factor-1, FGF-1141 (formerly called Cardio Vascu-Grow) and it facilitates the growth of new blood vessels in the heart tissues and organs with an impaired vascular system. This process is referred to as angiogenesis in the scientific community. The Company’s research and development is focused on developing new drug candidates, in which FGF-1141 is the API for the treatment of cardiovascular diseases, where the growth of new blood vessels can improve the outcome for patients. The Company conducts research to identify and evaluate medical indications that may benefit from its drug candidates.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.